Sutro Biopharma develops antibody drug conjugates, a type of cancer treatment, for patients with solid tumors. It last closed at $8.92 on Nov 17, down 4.29% on the day.
Only 1 firm rated STRO in the past 90 days, not enough for a consensus
Average 12-month target
$57.00
▲ 539.0% upside
Based on 1 analyst who set a price target on STRO in the past 90 days. The average target is $57.00, with a high of $57.00 and a low of $57.00, compared with the last close of $8.92.
Low $57.00Avg $57.00High $57.00
Blue marker: last close $8.92
Highest target$57.00
Average target$57.00
Lowest target$57.00
Latest rating changes
BarclaysTarget raised
Nov 13Buy$56 → $57
CitizensMaintained
Aug 13Buy$34
WedbushReiterated
Aug 13Buy$60
Truist SecuritiesAssumed coverage
Jun 11Buy$50
BarclaysInitiated
May 28Buy$56
Date
Firm
Action
Rating
Price target
Nov 13
Barclays
Target raised
Buy
$56 → $57
Aug 13
Citizens
Maintained
Buy
$34
Aug 13
Wedbush
Reiterated
Buy
$60
Jun 11
Truist Securities
Assumed coverage
Buy
$50
May 28
Barclays
Initiated
Buy
$56
Loading…
Technical Analysis
STRO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 7% below its 20 day and 43% below its 50 day average. It is 154% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the swing low (Nov 3) at $8.79, and the nearest resistance the Pivot at $8.98.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 10.9%/day
Key levels
$43.8552 week high+391.6%
$22.70200 day average+154.5%
$18.56100 day average+108.1%
$12.7650 day average+43.0%
$10.74Swing high (Nov 9)+20.4%
$9.5920 day average+7.5%
$9.30Pivot R1+4.3%
$8.98Pivot+0.7%
$8.92Last close
$8.79Swing low (Nov 3)−1.5%
$8.60Pivot S1−3.6%
$7.1552 week low−19.8%
Indicators
RSI (14)
35.03
Weak, oversold below 30
Neutral
MACD
-0.95
Above its signal line
Bullish
Stochastic
41.7
Middle of its range
Neutral
ADX (14)
46.2
Strong downtrend
Williams %R
-75.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-82.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−6.2%
Change over 10 sessions
Bearish
ATR (14)
$0.97
Typical daily range, 10.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 35.7%/day
Key levels
$43.8552 week high+391.6%
$22.70200 day average+154.5%
$18.56100 day average+108.1%
$12.7650 day average+43.0%
$10.74Swing high (Nov 9)+20.4%
$9.5920 day average+7.5%
$9.30Pivot R1+4.3%
$8.98Pivot+0.7%
$8.92Last close
$8.79Swing low (Nov 3)−1.5%
$8.60Pivot S1−3.6%
$7.1552 week low−19.8%
Indicators
RSI (14)
29.83
Oversold below 30
Oversold
MACD
-3.98
Below its signal line
Bearish
Stochastic
7.7
Near the bottom of its range
Oversold
ADX (14)
33.6
Trending down
Williams %R
-94.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-105.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−47.1%
Change over 10 sessions
Bearish
ATR (14)
$3.19
Typical daily range, 35.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for STRO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how STRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow STRO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How STRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STRO is in one of them and how their past STRO trades turned out.
Sutro Biopharma develops antibody drug conjugates, or ADCs, which are cancer treatments that link antibodies to cell-killing drugs. It uses its XpressCF protein synthesis platform to make these protein therapies, mainly for cancers. Its lead candidate, STRO-004, is in clinical trials for solid tumors. The company also works with pharmaceutical and biotechnology companies in oncology through research collaborations, and it is based in South San Francisco, California.